2-Year Lenalidomide Matches Lifelong Therapy in Standard-Risk Myeloma Trial
Phase III ENDURANCE trial finds fixed 2-year lenalidomide maintenance equals continuous therapy in overall survival, with fewer side effects.
Summary
A major phase III clinical trial called ENDURANCE found that patients with newly diagnosed, standard-risk multiple myeloma did not live longer when kept on continuous lenalidomide maintenance therapy compared to a fixed 2-year course. Both groups had nearly identical 7-year survival rates — around 69% — and similar progression-free survival. Importantly, patients on continuous therapy experienced more adverse effects without added benefit. These findings challenge the longstanding assumption in myeloma treatment that more therapy is always better. Researchers say modern induction treatments and improved relapse therapies may reduce the need for indefinite maintenance, pointing toward shorter, better-tolerated treatment strategies.
Detailed Summary
Multiple myeloma treatment has long defaulted to the assumption that continuous maintenance therapy prolongs survival. The ENDURANCE trial, published in the New England Journal of Medicine, directly challenges this dogma with rigorous prospective evidence.
The trial enrolled patients with standard-risk, newly diagnosed multiple myeloma who did not undergo upfront stem cell transplantation. After induction therapy with a proteasome inhibitor and lenalidomide, patients were randomized to either continuous lenalidomide maintenance or a fixed 2-year course. At 7 years, overall survival rates were virtually identical: 68.6% in the continuous group versus 69% in the fixed-duration group — a statistically insignificant difference. Median progression-free survival was also comparable at roughly 42 versus 39 months.
Critically, the continuous therapy arm generated more adverse events without producing measurable survival gains. Researchers concluded that the benefit of lenalidomide maintenance can be fully captured within a 2-year window, with extended treatment primarily adding toxicity rather than efficacy.
Editorialists from McMaster University and the University of Alabama at Birmingham praised ENDURANCE as a model for academically driven trials that ask not just which therapy to use, but for how long. They noted that industry-funded trials rarely test whether less treatment can be equally effective — a structural bias in oncology research.
For clinicians and patients, these findings carry immediate practical weight. Indefinite maintenance involves significant burden: cost, toxicity, quality-of-life impact, and logistical demands. A defined 2-year endpoint offers patients a clearer treatment horizon without compromising outcomes.
Caveats apply: the study focused on standard-risk patients not receiving stem cell transplants, so results may not generalize to high-risk disease or transplant-eligible populations. Still, ENDURANCE represents a meaningful shift in evidence-based myeloma management.
Key Findings
- 2-year lenalidomide maintenance matched continuous therapy in 7-year overall survival (~69% both groups).
- Continuous lenalidomide produced more adverse events without improving survival or progression-free survival.
- Median progression-free survival was similar: 42.5 months continuous vs 38.9 months fixed-duration.
- Results apply to standard-risk myeloma patients not receiving upfront stem cell transplantation.
- Trial supports asking not just which therapy to use, but for how long — challenging 'more is better' dogma.
Methodology
This is a news report summarizing results from the phase III ENDURANCE randomized controlled trial published in the New England Journal of Medicine, a high-credibility peer-reviewed journal. The trial provides prospective, randomized evidence comparing continuous versus fixed-duration lenalidomide maintenance in standard-risk newly diagnosed myeloma patients. Evidence quality is high given the RCT design and long 7-year follow-up.
Study Limitations
Findings are specific to standard-risk, newly diagnosed myeloma patients not undergoing upfront autologous stem cell transplantation and may not apply to high-risk or transplant-eligible patients. The article is a news summary and full trial data should be reviewed in the primary NEJM publication. Long-term relapse patterns beyond 7 years and quality-of-life metrics were not detailed in this report.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: